BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 6159573)

  • 1. [A reserve chemotherapy for Hodgkin's disease (author's transl)].
    Amiel JL; Ayed FB; Droz JP; Tursz T; Brule CH
    Nouv Presse Med; 1980 Oct; 9(37):2705-6. PubMed ID: 6159573
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pediatric Hodgkin's disease.
    Oliapuram Jose B; Koerner P; Bertolone S; Patel CC; Spanos WJ; Paris KJ; Silverman CL; Yashar CM
    J Ky Med Assoc; 2004 Mar; 102(3):104-6. PubMed ID: 15067795
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ABVD chemotherapy of Hodgkin's disease.
    Molnár Z; Schneider T; Várady E; Fleischmann T
    Neoplasma; 1997; 44(4):263-5. PubMed ID: 9473781
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) salvage of mechlorethamine, vincristine, prednisone, and procarbazine (MOPP)-resistant advanced Hodgkin's disease.
    Piga A; Ambrosetti A; Todeschini G; Cetto G; Perona G; Cellerino R
    Cancer Treat Rep; 1984; 68(7-8):947-51. PubMed ID: 6204754
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Complete remission of relapsed mixed cellularity Hodgkin's disease treated with rituximab].
    Al-Ali HK; Wittekind C; Niederwieser D
    Dtsch Med Wochenschr; 2007 Aug; 132(33):1688-91. PubMed ID: 17713864
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of childhood Hodgkin's disease with ABVD without radiotherapy.
    Behrendt H; Brinkhuis M; Van Leeuwen EF
    Med Pediatr Oncol; 1996 Apr; 26(4):244-8. PubMed ID: 8600335
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cyclic delivery of MOPP and ABVD combinations in Stage IV Hodgkin's disease: rationale, background studies, and recent results.
    Bonadonna G; Santoro A; Bonfante V; Valagussa P
    Cancer Treat Rep; 1982 Apr; 66(4):881-7. PubMed ID: 6176323
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Salvage chemotherapy in resistant malignant lymphomas (author's transl)].
    Tursz T; Ben Ayed F; Droz JP; Spielmann M; Amiel JL
    Bull Cancer; 1982; 69(1):28-32. PubMed ID: 6176284
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined modality therapy in previously untreated patients with advanced Hodgkin's disease: A 24-year follow-up study.
    Salloum E; Doria R; Farber LR; Roberts KB; Cooper DL
    Cancer J Sci Am; 1995; 1(4):267-73. PubMed ID: 9166487
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination chemotherapy with DTIC (NSC-45388) in advanced malignant melanoma, soft tissue sarcomas, and Hodgkin's disease.
    Beretta G; Bonadonna G; Bajetta E; Tancini G; De Lena M; Azzarelli A; Veronesi U
    Cancer Treat Rep; 1976 Feb; 60(2):205-11. PubMed ID: 769975
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Contribution of ABVD chemotherapy in refractory Hodgkin's disease. Study of 21 observations (author's transl)].
    Bauters F; Jouet JP; Huart JJ; Jude B; Goudemand M
    Sem Hop; 1980 May 18-25; 56(19-20):959-66. PubMed ID: 6158099
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine plus extended-field radiotherapy is superior to radiotherapy alone in early favorable Hodgkin's lymphoma: final results of the GHSG HD7 trial.
    Engert A; Franklin J; Eich HT; Brillant C; Sehlen S; Cartoni C; Herrmann R; Pfreundschuh M; Sieber M; Tesch H; Franke A; Koch P; de Wit M; Paulus U; Hasenclever D; Loeffler M; Müller RP; Müller-Hermelink HK; Dühmke E; Diehl V
    J Clin Oncol; 2007 Aug; 25(23):3495-502. PubMed ID: 17606976
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [DTIC--one component of ABVD combination therapy in Hodgkin's disease (author's transl)].
    Lutz D; Waldner R; Höcker P; Baumgartner G
    Wien Klin Wochenschr; 1978 Dec; 90(24):876-7. PubMed ID: 741755
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Feasibility study of application of international prognostic score on prediction of prognosis for advanced Hodgkin's lymphoma].
    Fu XH; Wang SS; Huang Y; Wang B; Huang HQ; Zhang L; Sun XF; Xu RH; Lin TY
    Ai Zheng; 2006 Aug; 25(8):1013-8. PubMed ID: 16965685
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chemotherapy strategies to improve the control of Hodgkin's disease: the Richard and Hinda Rosenthal Foundation Award Lecture.
    Bonadonna G
    Cancer Res; 1982 Nov; 42(11):4309-20. PubMed ID: 6181867
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized comparison of ABVD chemotherapy with a strategy that includes radiation therapy in patients with limited-stage Hodgkin's lymphoma: National Cancer Institute of Canada Clinical Trials Group and the Eastern Cooperative Oncology Group.
    Meyer RM; Gospodarowicz MK; Connors JM; Pearcey RG; Bezjak A; Wells WA; Burns BF; Winter JN; Horning SJ; Dar AR; Djurfeldt MS; Ding K; Shepherd LE; ;
    J Clin Oncol; 2005 Jul; 23(21):4634-42. PubMed ID: 15837968
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ABVD plus subtotal nodal versus involved-field radiotherapy in early-stage Hodgkin's disease: long-term results.
    Bonadonna G; Bonfante V; Viviani S; Di Russo A; Villani F; Valagussa P
    J Clin Oncol; 2004 Jul; 22(14):2835-41. PubMed ID: 15199092
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relapse and late complications in early-stage Hodgkin's disease patients with mediastinal involvement treated with radiotherapy alone or plus one cycle of ABVD.
    Enrici RM; Anselmo AP; Donato V; Falchetto Osti M; Santoro M; Tombolini V; Mandelli F
    Haematologica; 1999 Oct; 84(10):917-23. PubMed ID: 10509040
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Ten-year outcomes of lymphogranulomatosis treatment according to the protocol MOPP-ABVD+radiotherapy].
    Pivnik AV; Rastrigin NA; Moiseeva TN; Lutsenko IN; Dudarova RG; Shavlokhov VS; Efimov IV; Kozhurin SV; Shitareva IV; Gemdzhian EG; Tsyba NN; Kolosova LIu; Melikian AL; Skidan NI; Pan'shin GA; Sotnikov VM; Dotsenko PV; Nechistiuk AV
    Ter Arkh; 2006; 78(8):57-62. PubMed ID: 17078219
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Etoposide, vinblastine, adriamycin and prednisolone (EVAP) combination chemotherapy as first-line treatment for Hodgkin's disease.
    Raina V; Sharma A; Mohanti BK; Kumar R; Dawar R; Rath GK
    Natl Med J India; 2003; 16(4):199-203. PubMed ID: 14606767
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.